While both berberine and Ozempic may lead to weight loss, they are very different things. It’s “inaccurate and misleading” to ...
In this morning’s readout from Novo's phase 2 trial of monlunabant in 243 people with obesity and metabolic syndrome, it ...
Dr. Patricia Brubaker and Dr. Pieter Cohen are the speakers at this year’s Trottier Public Science Symposium, Monday at 7 p.m. at McGill University’s Leacock Building, Room 132. Admission is free, but ...
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some ...
Investor's Business Daily on MSN45m
Novo Dives — And Corbus Crashes — After New Weight-Loss Drug Causes Neuropsychiatric EffectsNovo Nordisk stock tumbled Friday — pulling Corbus Pharmaceuticals into a steep dive — after its new approach to weight loss caused neuropsychiatric side effects.Please watch the video at ...
Eli Lilly (NYSE:LLY) is taking the unusual step of asking people who took compounded versions of their drug tirzepatide, ...
Investment returns and principal value will vary; there may be a gain or loss when shares are sold ... Pharmaceuticals led the sector, thanks in part to growing demand for GLP-1 obesity and diabetes ...
Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback